IONS

In a report released today, Gary Nachman from BMO Capital reiterated a Buy rating on Ionis Pharmaceuticals (IONS - Research Report), with a price target of $70.00. The company's shares opened today at $44.48.Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and AbbVie. According to TipRanks, Nachman has an average return of -9.1% and a 40.76% success rate on recommended stocks. In addition to BMO Capital, Ionis Pharmaceuticals also received a Buy from Needham's Joseph Stringer in a report issued yesterday. However, today, Citigroup maintained a Sell rating on Ionis Pharmaceuticals (NASDAQ: IONS).
https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-their-buy-rating-for-ionis-pharmaceuticals-ions?utm_source=advfn.com&utm_medium=referral